Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human|
|Published species reactivity||Not Applicable|
|Host / Isotype||Goat / IgG|
|Immunogen||Gamma Immunoglobins Heavy and Light chains|
|Conjugate||Alexa Fluor® 546|
|Storage buffer||PBS, pH 7.5|
|Contains||5mM sodium azide|
|Storage Conditions||4° C, store in dark|
|Cross Adsorption||Against mouse, rabbit and bovine serum prior to conjugation|
|Antibody Form||Whole Antibody|
|Tested Applications||Dilution *|
|Immunocytochemistry (ICC)||1-10 µg/ml|
|Immunofluorescence (IF)||1-10 µg/mL|
|Immunohistochemistry (IHC)||1-10 µg/ml|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Miscellaneous PubMed (MISC)||See 5 publications below|
Anti-Human secondary antibodies are affinity-purified antibodies with well-characterized specificity for human immunoglobulins and are useful in the detection, sorting or purification of its specified target. Secondary antibodies offer increased versatility enabling users to use many detection systems (e.g. HRP, AP, fluorescence). They can also provide greater sensitivity through signal amplification as multiple secondary antibodies can bind to a single primary antibody. Most commonly, secondary antibodies are generated by immunizing the host animal with a pooled population of immunoglobulins from the target species and can be further purified and modified (i.e. immunoaffinity chromatography, antibody fragmentation, label conjugation, etc.) to generate highly specific reagents.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
|Not Applicable||Not Cited||Fully synthetic polymer vesicles for intracellular delivery of antibodies in live cells.||Canton I,Massignani M,Patikarnmonthon N,Chierico L,Robertson J,Renshaw SA,Warren NJ,Madsen JP,Armes SP,Lewis AL,Battaglia G||FASEB journal : official publication of the Federation of American Societies for Experimental Biology (27:98)||2013|
|Not Applicable||Not Cited||LFA-1 is a key determinant for preferential infection of memory CD4+ T cells by human immunodeficiency virus type 1.||Tardif MR,Tremblay MJ||Journal of virology (79:13714)||2005|
|Not Applicable||Not Cited||Development of a novel FRET immunosensor technique.||Lichlyter DJ,Grant SA,Soykan O||Biosensors & bioelectronics (19:219)||2003|
|Not Applicable||Not Cited||Functional human immunodeficiency virus type 1 (HIV-1) Gag-Pol or HIV-1 Gag-Pol and env expressed from a single rhabdovirus-based vaccine vector genome.||McGettigan JP,Naper K,Orenstein J,Koser M,McKenna PM,Schnell MJ||Journal of virology (77:10889)||2003|
|Not Applicable||Not Cited||Second-generation rabies virus-based vaccine vectors expressing human immunodeficiency virus type 1 gag have greatly reduced pathogenicity but are highly immunogenic.||McGettigan JP,Pomerantz RJ,Siler CA,McKenna PM,Foley HD,Dietzschold B,Schnell MJ||Journal of virology (77:237)||2003|